Direct-compression manufacture of low-dose veterinary tablets containing strychnine hydrochloride begins with particle-size control of the API, not with final blend potency adjustment. In jurisdictions where strychnine remains authorized under national poison schedules for non-food-animal uses, the single-unit active content is typically held below 0.30 mg because of the extremely narrow therapeutic margin. The API is milled or air-jet micronized until the particle-size distribution reaches D90 ≤ 20 µm, a threshold that reduces the formation of superpotent aggregates during transfer and blending. Geometric dilution is performed in 1:1 increments with a previously screened filler-binder system composed of spray-dried lactose monohydrate and dibasic calcium phosphate dihydrate. Each dilution step is discharged through a 250 µm stainless-steel hand screen before the next addition.

Final blending is performed in a bin blender with an intensifier bar at 12 rpm for 15 min; the vessel fill volume is maintained between 50% and 70% to avoid stagnant sections along the walls. Tablet compression is carried out on a rotary tablet press equipped with a force feeder and 6.0 mm or 7.0 mm round punches. The compression force is held between 6 kN and 18 kN, producing tablets with hardness 40–80 N and thickness 2.5–3.5 mm. In-process weight is checked with a check weigher at 15 min intervals; individual tablet mass is set at 80–150 mg depending on punch diameter. Content uniformity is evaluated per USP <905> with an acceptance value not exceeding 15.0. Segregation control requires stratified sampling from the discharge chute at the beginning, middle, and end of compression.

Excipients are selected for stability rather than compressibility alone. Sodium starch glycolate is used at 2–5% w/w as a disintegrant; crospovidone is excluded because its moisture uptake can introduce variable water activity in hygroscopic alkaloid-salt blends. Magnesium stearate is limited to 0.5% w/w and is blended for not more than 3 min after lubricant addition. Higher lubricant levels can lower tablet tensile strength and delay dissolution of low-solubility strychnine salts. Dissolution testing, where a regional pharmacopoeial monograph is absent, uses USP <711> apparatus 2 at 50 rpm in 900 mL of 0.1 N hydrochloric acid. Published data for direct compression of strychnine veterinary tablets under high-humidity production conditions remains limited; transfer of compression parameters from other potent alkaloid salts therefore requires a risk assessment and full factorial validation.

Which in-process controls prevent assay drift in aqueous injections below 0.5 mg/mL?

Aqueous injectable solutions of strychnine salts are compounded in Water for Injection with a pH target of 3.0–4.5. The pH range is not arbitrary; below 3.0, some glass vials and rubber stoppers show elevated extractables, and above 5.5, the free alkaloid progressively loses water solubility and can form visible particles during storage. The bulk solution is purged with nitrogen for at least 20 min before addition of the API and maintained under a nitrogen overlay throughout compounding. Dissolved oxygen is measured with a polarographic probe and held below 1.0 mg/L to reduce oxidative degradation of the indole-type alkaloid nucleus. The API is pre-dissolved in a 10% portion of the final batch volume before transfer to the main vessel to avoid localized concentration gradients.

Filtration is performed through a 0.22 µm PVDF or PES membrane at 20–25 °C. Nylon membranes are avoided because the low-concentration basic drug can adsorb onto the membrane surface, producing assay losses that may exceed 5.0% in unbuffered aqueous systems. Terminal moist-heat sterilization is designed according to ISO 17665-1:2006 with a minimum F0 of 8.0 min at 121.1 °C. A forced degradation study under ICH Q1A(R2) must demonstrate assay loss not greater than 5.0% at the proposed F0 and pH endpoints. Aseptic filling occurs in an ISO Class 5 environment according to ISO 14644-1:2015, using rotary piston or peristaltic pumps with gravimetric fill verification every 15 min.

In-process assay samples are withdrawn from the filling line at 30 min intervals and tested by HPLC with UV detection at 254 nm. Release limits for the active are set at 95.0–105.0% of labeled content. Particulate matter is controlled according to USP <788>, and container quality is verified against USP <660> for Type I borosilicate glass. Because the therapeutic index of strychnine is extremely narrow, an independent verification of all weighings, pH adjustments, and filter integrity test results is recorded in the batch manufacturing record. Published data for strychnine injection stability under terminal sterilization in amber glass is limited; bracketing studies at pH 3.0 and 4.5 are required before scale-up.

Encapsulation constraints for high-potency powder blends in hard gelatin shells

Hard gelatin capsule filling of strychnine hydrochloride is performed on dosator or tamping-pin machines using size 3 or 4 shells. The fill weight is maintained at 100–160 mg, which allows sufficient excipient bulk for a low active content below 0.30 mg without over-diluting the blend to an unmixable free-flow state. The API is pre-milled to D90 ≤ 20 µm and geometrically diluted with lactose monohydrate or mannitol. Both fillers are sieved through a 250 µm screen and dried to a loss-on-drying value below 1.0% before use. Blend uniformity is tested before capsule filling according to ASTM E2810-11 with a target relative standard deviation not exceeding 5.0%. Stratified samples are taken from 10–20 locations across the blender discharge, including dead legs and the center of the vessel.

During filling, the powder bed is held under controlled ambient conditions at 20–25 °C and 30–45% RH. Gelatin shells become brittle below 40% RH, while hygroscopic fillers can increase moisture above 50% RH and reduce powder flow. Fill-weight control is gravimetric, with a target of ± 3.0% of the nominal fill weight for a size 4 shell. Capsule closure is checked mechanically every 15 min; tampered or loose shells are rejected by a check weigher and visual inspection channel. Dissolution testing for each capsule batch uses USP <711> apparatus 2 at 50 rpm in 900 mL of 0.1 N hydrochloric acid with wire sinkers. A validated method under ICH Q2(R1) is required because published dissolution data for strychnine veterinary capsules in this medium is limited. Capsules are packaged in PVC/PVDC blister cavities with a desiccant canister, and stability is assigned to 25 °C/60% RH or 30 °C/65% RH according to the intended climatic zone.

When wet granulation of a veterinary premix shifts from low-shear to high-shear processing

A veterinary premix containing strychnine at 0.1% w/w or lower imposes a carrier-to-active ratio of approximately 99.9:0.1. This dilution ratio creates a homogeneity risk that cannot be corrected by extending blend time alone. Wet granulation is introduced when dry blending fails to control segregation during downpacking, transfer, and end-user feed incorporation. Low-shear planetary mixing at 20–40 rpm produces granules with bulk density 0.45–0.60 g/mL, while high-shear processing at tip speeds of 3–7 m/s and chopper speeds of 1000–1500 rpm densifies the granule to 0.65–0.85 g/mL. The shift from low-shear to high-shear does not simply increase yields; it changes binder solution demand, wet massing time, and post-dry particle-size distribution.

In a high-shear granulator, binder solution addition volume is reduced by 20–30% relative to a low-shear process because mechanical shear distributes liquid more efficiently across the powder bed. Wet massing is limited to 90–180 s to prevent over-granulation, which would reduce the 150–850 µm sieve fraction and increase fine generation during milling. Drying is performed in a fluid-bed dryer with inlet air at 50–60 °C and product temperature not exceeding 45 °C. The process is stopped when loss on drying according to ISO 6496:1999 is ≤ 2.0%. Undersized fines below 150 µm are limited to ≤ 15% of the finished granule mass to reduce active-rich demixing during bulk transport. Sampling of the premix follows ISO 6497:2002; composite samples are tested for active content by HPLC. Because the active concentration is low, a potency window of ± 10% of declared content is commonly applied as an in-process control limit. Strychnine-containing premixes are handled under controlled-substance and poison-schedule procedures in most jurisdictions, and cleaning validation must demonstrate absence of cross-contamination in subsequent batches.

Aqueous oral drench formulations containing strychnine salts are compounded at 0.05–0.20 mg/mL in purified water adjusted to pH 3.0–4.0 with citric acid or dilute hydrochloric acid. The acidic environment keeps the alkaloid in its protonated, water-soluble form and supports the antimicrobial activity of sodium benzoate when used at 0.1% w/v. Mixing is conducted in a jacketed stainless-steel vessel under vacuum and nitrogen overlay. The API is pre-dissolved in a 10% fraction of the final batch volume before transfer to the main mixer; this step reduces the risk of high-concentration zones that can form as the salt hydrates and dissolves. Propeller agitation is run at 150–300 rpm, sufficient to dissolve the salt without drawing air into the liquid surface. The solution is passed through a 75 µm inline screen before packaging to remove trace undissolved material.

After compounding, the solution is transferred under positive pressure to a packaging line with amber Type III glass or high-density polyethylene containers. Headspace oxygen is controlled by nitrogen sparging followed by continuous purge; residual headspace oxygen is limited to ≤ 2.0% before capping. Stability for oral solutions is evaluated according to ICH Q1A(R2) at 25 °C/60% RH and 30 °C/65% RH as appropriate for the intended climatic zone. Photostability is performed under ICH Q1B because the indole-type alkaloid ring is sensitive to ultraviolet exposure; amber packaging is qualified by light transmission measurements. Non-sterile aqueous dosage forms are handled with closed transfer vessels and negative room pressure relative to surrounding corridors; all equipment is cleaned with acidified rinse solutions followed by swab verification. Because published hold-time data for strychnine oral solutions in HDPE is limited, batch-specific bracketing studies at pH 3.0 and 4.0 are required before commercial distribution.

Dry granule adsorption onto feed-grade carriers and the associated segregation threshold

Dry granule premixes for non-food-animal applications often rely on adsorption of a strychnine ethanolic or aqueous solution onto feed-grade calcium carbonate, maltodextrin, or silica-coated starch. The carrier is selected according to oil absorption capacity, tapped bulk density, and residual moisture content. Calcium carbonate with a skeletal density of 2.7–2.9 g/cm³ provides a high-density carrier that resists windage losses during feed-mill transfer, while starch-based carriers at 0.5–0.7 g/cm³ offer higher liquid absorption but create dust. A segregation threshold appears when the carrier particle-size distribution contains more than a 2:1 weight ratio between the fraction larger than 850 µm and the fraction smaller than 150 µm. Active-rich fines then migrate to the bottom of multi-walled paper bags during road transport, causing potency drift between first and final discharge samples.

Roller compaction is used to densify the loaded granule and reduce dust generation. Gap width is set at 0.8–1.5 mm with roll force of 8–15 kN/cm, producing bulk density in the range of 0.60–0.90 g/mL. Milled granules are screened to 150–850 µm; oversize material is recycled through the mill, while undersized fines are recompacted to avoid uncontrolled active-rich dust. Packaging is performed in antistatic polyethylene liners inside fiber drums or paper sacks. Sampling according to ISO 6497:2002 is performed at a minimum of 10 points per tonne, and the coefficient of variation for active content is held at ≤ 5.0%. Published data for strychnine-specific adsorption equilibrium onto calcium carbonate is limited; adsorption isotherms must be generated at 25 °C and 40 °C to confirm that desorption does not occur during tropical storage or transshipment.